BioSpace News Archive

Quidel Corporation announced that Quidel has received funding from the Biomedical Advanced Research and Development Authority to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus.

CRH Medical Corporation, announces the following voting results for the Company’s 2020 Annual General Meeting of Shareholders.

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is supporting Professor Sachin Gupte, a pharmacologist at the New York Medical College (Valhalla, NY, USA), in his endeavours to find a drug treatment for the lung damage that can result from Covid-19 infection. S

Approximately 7.5 million people in the U.S.1 have psoriasis, a chronic inflammatory disease that mostly affects the skin and joints but could also affect the nails.

Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studies In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD 1 TOKYO &

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18 at 1:40 p.m. Eastern Time.

Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of 14,400,000 shares of common stock at a public offering price of $18.00 per share.